RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

As I said, this doesn't set a high benchmark for valuation. It depends on whether Cortex can generate any interest elsewhere in CSA/low impacts or high impacts for neurodegeneration, building from this option exercise. Living in SoCal, where there is a lot of media coverage of the Michael Jackson trial, and the discussion regarding propofol risks, one would think some interest might percolate around the more general RD application, but then again, I've thought that before.

Bottom line: It depends on whether Servier continues to be the only interested party as the funds dwindle.

NeuroInvestment